MARKET

KRYS

KRYS

Krystal Biotech
NASDAQ
333.54
+1.27
+0.38%
Opening 12:58 08/17 EDT
OPEN
330.31
PREV CLOSE
332.27
HIGH
335.91
LOW
330.06
VOLUME
52.74K
TURNOVER
--
52 WEEK HIGH
382.54
52 WEEK LOW
136.73
MARKET CAP
9.87B
P/E (TTM)
41.82
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KRYS last week (0810-0814)?
Weekly Report · 6h ago
Krystal Biotech initiated with an Outperform at RBC Capital
TipRanks · 1d ago
Micron upgraded, Cisco downgraded: Wall Street’s top analyst calls
TipRanks · 1d ago
Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?
Simply Wall St · 1d ago
High-Profile Insider Trade Shakes Up Krystal Biotech
TipRanks · 2d ago
Krystal Bio granted bullish view at RBC after blockbuster projections
Seeking Alpha · 3d ago
Krystal Biotech Price Target Announced at $400.00/Share by RBC Capital
Dow Jones · 3d ago
Krystal Biotech Initiated at Outperform by RBC Capital
Dow Jones · 3d ago
More
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

Webull offers Krystal Biotech Inc stock information, including NASDAQ: KRYS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KRYS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KRYS stock methods without spending real money on the virtual paper trading platform.